Patients with dermatomyositis are more likely to develop cancer if they are positive for anti-transcriptional intermediary factor 1 (TIF1) antibodies than if they are negative (HR 3.4 (95% CI 2.2–5.4)), according to the results of a UK study of 263 patients. During a 10-year follow-up period, cancer occurred exclusively within a 3-year window either side of diagnosis in anti-TIF1 antibody-positive patients and was most common in patients over the age of 39. Patients with anti-TIF1 antibodies also had a higher risk of ovarian cancer than those without (19% of cancers versus 2% of cancers, respectively; P < 0.05).
References
Original article
Oldroyd, A. et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology https://doi.org/10.1093/rheumatology/key357 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Cancer risk associated with anti-TIF1 antibodies. Nat Rev Rheumatol 15, 64 (2019). https://doi.org/10.1038/s41584-019-0164-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0164-3
